

Press Release

August 15, 2025

TOWA PHARMACEUTICAL CO., LTD.

Towa Receives Manufacturing and Marketing Approval for generic drugs

Osaka, Japan, August 15, 2025 – Towa Pharmaceutical Co., Ltd. (Head office: Kadoma, Osaka; President: Itsuro Yoshida) has received approval from the Ministry of Health, Labour and Welfare to manufacturing and marketing the following five ingredients and six items of generic drugs.

《The list of approved products》

1. EFINACONAZOLE TOPICAL SOLUTION

Product name	EFINACONAZOLE TOPICAL SOLUTION 10% "TOWA"
Brand-name drugs	CLENAFIN Topical Solution

2. OSELTAMIVIR DS

Product name	OSELTAMIVIR DS 3% "TOWA"
Brand-name drugs	TAMIFLU Dry Syrup

3. LACOSAMIDE DS

Product name	LACOSAMIDE DS 10% "TOWA"
Brand-name drugs	VIMPAT DRY SYRUP 10%

4. LANTHANUM CARBONATE HYDRATE OD TABLETS

Product name	LANTHANUM CARBONATE OD TABLETS 250mg "TOWA"/ OD TABLETS 500mg "TOWA"
Brand-name drugs	Fosrenol OD tablets 250mg/500mg

5. EPINASTINE HYDROCHLORIDE OPHTHALMIC SOLUTION

Product name	EPINASTINE HYDROCHLORIDE OPHTHALMIC SOLUTION 0.05% "TW"
Brand-name drugs	ALESION Ophthalmic Solution

Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

[Inquiries]

Public Relations and Investor Relations Department, Towa Pharmaceutical Co., Ltd.

2-11 Shinbashi-cho, Kadoma, Osaka 571-8580, Japan

Tel: +81-6-6900-9102 / Email: kouhou@towayakuhin.co.jp